Business Context and Reporting Period
This Form 8-K, dated April 27, 2021, reports the completion of a merger between Palisade Bio, Inc. (formerly Seneca Biopharma, Inc.) and Leading Biosciences, Inc. (LBS). The transaction resulted in LBS becoming a wholly-owned subsidiary of Palisade Bio. Concurrently, the Company changed its name from Seneca Biopharma, Inc. to Palisade Bio, Inc., and its ticker symbol changed from "SNCA" to "PALI" on the Nasdaq Capital Market. The Company also effected a 1-for-6 reverse stock split immediately prior to the merger effective time.
Key Financial Metrics and Capital Structure
The filing details a Pre-Merger Financing transaction completed on April 27, 2021, involving an aggregate purchase price of $20,000,000 in cash plus the cancellation of outstanding principal and interest on notes previously issued to the investor. The purchase price per share was $0.4816 (pre-split). Immediately following the effective time, approximately 7,323,935 shares of Company Common Stock were outstanding, excluding 3,977,676 shares held in escrow. Former LBS equityholders own approximately 74.29% of the fully-diluted Company Common Stock, while pre-merger Palisade stockholders own approximately 25.71%. The filing does not provide specific revenue, profit, cash flow, or debt figures for the combined entity at this time.
Material Changes Versus Prior Period
- Corporate Identity: Name changed from Seneca Biopharma, Inc. to Palisade Bio, Inc.
- Business Focus: The Company's primary business is now the clinical-stage biopharmaceutical operations of LBS, focused on gastrointestinal function following major surgery.
- Capitalization: Implementation of a 1-for-6 reverse stock split and issuance of new shares to LBS shareholders and investors.
- Leadership: Complete turnover of the Board of Directors and Executive Officers. Former Seneca leadership (Kenneth Carter, Dane Saglio, Matthew Kalnik) resigned or were terminated. New leadership includes Thomas Hallam, Ph.D. (CEO), J.D. Finley (CFO), and Michael Dawson, M.D. (CMO).
Guidance, Outlook, Risks, and Unusual Items
Contingent Value Rights (CVRs): The Company entered into a CVR Agreement entitling pre-merger stockholders to 80% of net proceeds from the sale or license of "Seneca Legacy Technology" within 18 months of the merger. These rights are non-transferable and have no voting or dividend rights.
Pre-Merger Financing Terms: The financing includes an escrow arrangement where additional shares may be issued to the investor if the Company's stock price falls below the purchase price during specific 10-day periods following the merger. Equity Warrants were also issued to the investor with a five-year term.
Executive Compensation: New employment agreements were executed with base salaries of $490,000 (CEO), $400,000 (CFO), and $115,900 (CMO). Significant closing bonuses were paid ($285,000, $231,000, and $66,000 respectively). Severance provisions include salary continuation and equity acceleration upon termination without cause or resignation for good reason.
Financial Reporting: The filing states that financial statements of LBS and pro forma financial information will be filed in an amendment to this report within 71 calendar days.
Investor Verification Checklist
- Verify the final ownership percentage of former LBS shareholders versus former Seneca shareholders (74.29% vs 25.71%).
- Review the terms of the Contingent Value Rights Agreement regarding the monetization of Seneca Legacy Technology.
- Monitor the escrow conditions for the Pre-Merger Financing investor, specifically the price thresholds that trigger additional share issuances.
- Confirm the filing of LBS financial statements and pro forma information within the 71-day window.
- Assess the impact of the new executive compensation structure on future cash burn and equity dilution.